MedRhythms announces reportedly a first-of-its-kind partnership with Universal Music Group (UMG) that provides MedRhythms with access to UMG’s music catalog to provide prescription music to patients with neurological conditions.
MedRhythms’ platform is based on neuroscience that demonstrates how music can profoundly impact the human brain, target specific neural circuitry to enhance clinical outcomes and boost neuroplasticity.
In addition to enabling MedRhythms to deliver prescription music to patients, Universal Music Group for Brands, UMG’s global brands partnership team, will provide MedRhythms with resources and insights related to data analytics, cultural intelligence and marketing.
UMG’s partnership with MedRhythms began as a collaboration between UMG for Brands and Havas Health, according to a media release from MedRhytms.
Music is Curated and Screened
MedRhythms’ digital therapeutics use music content that is curated and screened via the company’s patented process, which carefully selects and customizes interventions to each user. The process initially analyzes the content for the right characteristics to make it therapeutically valuable for the patients and, once this step is complete, it curates clinical interventions for each individual patient.
Research supports that preferred music content increases adherence to treatment and improves therapeutic outcomes, which is why providing patients with music they enjoy is a critical component of the system and why the company’s partnership with UMG is meaningful and important.
“Music has the power to transcend borders, cultures and languages to connect people and elevate the quality of life around the world. Now, with MedRhythms, we’re seeing the power of music harnessed to heal.
“Our innovative collaboration with MedRhythms will enable UMG to help enhance neurologic treatment for patients across the US. We’ve played a central role in promoting music’s growing importance throughout the health and wellness industry—fitness, sleep, meditation—and in this pioneering alliance, we’re privileged to be engaged in extending music’s profound impact to medical therapy.”
— Michael Nash, UMG’s Executive Vice President of Digital Strategy
MedRhythms and UMG are reportedly the first companies to develop an FDA-approved, prescription music platform, the release continues.
MedRhythms is developing a patented platform of evidence-based, prescription digital therapeutics using music to address walking impairments. This platform is based on neuroscience research that shows that auditory rhythm can be used to directly target the human motor system to address walking deficits caused by neurologic injuries and diseases, including stroke, multiple sclerosis (MS), Parkinson’s disease (PD), Alzheimer’s disease and cognitive impairment, and aging-in-place.
“Partnering with UMG is a milestone for MedRhythms that will unlock innumerable doors to improving the quality of care we deliver to patients. We are humbled and honored to be collaborating with the world leaders in music-based entertainment and matching this with our world-class scientific team to continue to push the envelope in both music and medicine while making a significant impact in the lives of patients who desperately need this care. This partnership will afford us the opportunity to leverage patient-preferred music to provide top clinical outcomes and build a product that patients are excited to use.”
— Brian Harris, CEO and co-founder of MedRhythms
[Source(s): MedRhythms, Business Wire]
Related Content:
MedRhythms Launches Clinical Trial of Stroke Asset on Walking Outcomes
MedRhythms Launches Clinical Trial to Study Digital Therapeutic in Parkinson’s Disease
MedRhythms Advances Pipeline of Products in MS and Parkinson’s
